Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 CFR Part 201—Labeling
21 CFR Part 201—Labeling, “Labeling”, is a CFR part of 21 CFR Chapter I, Subchapter C—DRUGS: GENERAL; it is made under 42 laws; in force.
https://ontology.bommaritollc.com/id/01a0f094-b837-76de-94de-1fdabf2c1fc1
Elsewhere
Facts
| adms:identifier | |
| authority note | 21 U.S.C. 321, 331, 343, 351, 352, 353, 355, 358, 360, 360b, 360ccc, 360ccc-1, 360ee, 360gg-360ss, 371, 374, 379e; 42 U.S.C. 216, 241, 262, 264.en |
| eli:based_on | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 CFR Part 201 |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Labelingen |
| schema:url | |
| skos:prefLabel | 21 CFR Part 201—Labelingen |
| source note | 40 FR 13998, Mar. 27, 1975, unless otherwise noted.en |
Related
Cited by (8)eli:cites
- 21 CFR 207.1 What definitions and interpretations of terms apply to this part?
- 21 CFR 251.13 Labeling of eligible prescription drugs.
- 21 U.S.C. 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application
- FR Doc. 2023-11354: Medication Guides: Patient Medication Information
- FR Doc. 2024-04840: Labeling Requirements for Approved or Conditionally Approved New Animal Drugs
- FR Doc. 2024-11229: Labeling Requirements for Approved or Conditionally Approved New Animal Drugs; Extension of Comment Period
- FR Doc. 2026-08826: Modification of Certain Terminology in Title 21
- FR Doc. 2026-15671: Modification of Certain Terminology in Title 21; Reopening of the Comment Period
Parts (7)schema:isPartOf
- 21 CFR Part 201, Subpart A—General Labeling Provisions
- 21 CFR Part 201, Subpart B—Labeling Requirements for Prescription Drugs and/or Insulin
- 21 CFR Part 201, Subpart C—Labeling Requirements for Over-the-Counter Drugs
- 21 CFR Part 201, Subpart D—Exemptions From Adequate Directions for Use
- 21 CFR Part 201, Subpart E—Other Exemptions
- 21 CFR Part 201, Subpart F—Labeling Claims for Drugs in Drug Efficacy Study
- 21 CFR Part 201, Subpart G—Specific Labeling Requirements for Specific Drug Products
Its changes, from (5)eli:changes
- FR Doc. 2024-13190: Current Good Manufacturing Practice, Certification, Postmarketing Safety Reporting, and Labeling Requirements for Certain Medical Gases
- FR Doc. 2024-30261: Nonprescription Drug Product With an Additional Condition for Nonprescription Use
- FR Doc. 2025-01840: Nonprescription Drug Product With an Additional Condition for Nonprescription Use
- FR Doc. 2025-04978: Nonprescription Drug Product With an Additional Condition for Nonprescription Use
- FR Doc. 2026-04368: Revising the National Drug Code Format and Drug Label Barcode Requirements